卵巢癌免疫治疗的预后预测指标

Prognostic Indicators of Ovarian Cancer in Immunotherapy

卵巢癌自身具有免疫原性并可被宿主免疫系统识别和攻击,免疫系统在卵巢癌的发病机制、疾病进展中起着非常重要的作用。近年来,多腺苷二磷酸核糖聚合酶抑制剂、抗血管生成药物和靶向同源重组缺陷等治疗药物已在卵巢癌维持治疗中得到广泛应用,这些药物极大地改善了患者的预后,显著提高了卵巢癌患者的生存期,延缓了复发。随着免疫治疗在临床中的不断应用,探索能够用于评估卵巢癌免疫治疗预后的相关预测指标极为重要,有效、便捷的预后指标能够为临床医师的诊疗及决策提供参考,目前评估卵巢癌预后的预测指标仍是面临的难题之一。综述免疫评分、程序性细胞死亡受体1、中性粒细胞与淋巴细胞比值、骨髓源性抑制细胞等指标在卵巢癌免疫治疗预后中的预测价值。

Ovarian cancer has its own immunogenicity and can be recognized and attacked by the host immune system,which plays a very important role in the pathogenesis and disease progress of ovarian cancer.In recent years,drugs such as poly-adenosine diphosphate polymerase inhibitors,anti-angiogenesis drugs and targeted homologous recombination defects have been widely used in the maintenance treatment of ovarian cancer.These drugs have greatly improved the prognosis of patients,significantly improved the survival time of ovarian cancer patients,and delayed the recurrence.With the continuous application of immunotherapy in clinic,it is extremely important to explore the relevant predictive indicators that can be used to evaluate the prognosis of ovarian cancer immunotherapy.Effective and convenient prognostic indicators can provide reference for clinicians′diagnosis,treatment and decision-making.At present,it is still one of the difficulties to evaluate the prognostic indicators of ovarian cancer.This paper reviews the predictive value of immune score,programmed cell death receptor 1,neutrophil-to-lymphocyte ratio,bone marrow-derived suppressor cells and other indicators in the prognosis of ovarian cancer immunotherapy.